OMx Personal Health Analytics Inc.: federal grants and contributions: 8 agreements; $3.2M value; 2 departments; 6 programs.
Assay record ASY-CA-10LSKC31F4 · Cite as: Assay Systems, “OMx Personal Health Analytics Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/omx-personal-health-analytics-inc/
As part of EUREKA - Clusters ITEA Program, the project "ITEA - 23042 - AIDESL - Fully Automated AI Data Extraction from Scientific Literature" seeks to work globally with11 partners across 6 countries to establish methodological standards for AI LLM’s use to reduce the time it takes to complete a systematic literature review (SLR), accelerate time to market impact of SLRs use for regulatory submissions, and lower reviewer fatigue and burnout from their overall manual conduct of SLRs. The Firm will specifically assist in the partnership via three work packages: development of AI and LLM techniq
Expand functionality and markets for pharmaceutical analytical software
This will be an extension of Firm's previous IRAP project which involved enhancing its internal AI NLU tool with greater predictive and insight-generation capability as well as building the bridge between the tool and human-powered curation. In this project, Firm will leverage recent advances in generative AI and large language models (LLMs) to further enhance its technologies in three ways: through advanced queries, advanced evidence source identification, and through fully automated data generation.
This will be an extension of our previous IRAP grant (2019-2020) which involved building our internal AI NLU tool (called Mavin). In this project, we will focus on enhancing Mavin with greater predictive and insight-generation capability as well as building the bridge between Mavin and human-powered curation. To accomplish this, Mavin will be tightly integrated into our Knowledge Core (the knowledge graph powering existing products). This integration will occur at the data level, normalizing and linking evidence to human decisions, as well as through intuitive interfaces our curators will use
Develop and integrate Natural Language Processing (NLP) into current products and technologies. This will create efficiencies in our current curation practices and amplify our service offering to our current and future customers.
The project will include the addition and curation of new types of data and data sets for our drug information database including adding more detailed information about drugs that are currently in clinical trials, and developing marketing materials for recent additions to the database including drugs in clinical trials, a new API for the drug information related to drugs in clinical trials and developing expanded marketing strategies for our data products.
Attendance at the 3rd Annual Artificial Intelligence in Drug Development Congress to connect with over 450 AI and Pharma IT reps from leading biotech companies, global pharma organizations and renowned academic institutions.
This is a part of our ongoing project to develop a knowledge base of pharmaceutical knowledge for the purpose of prescription analysis using artificial intelligence and AI. The project entails integrating detailed knowledge about drugs, drug targets, drug-drug interactions and other scientific information about pharmaceuticals into the knowledge base.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.